All In Biotech

Drug Trial Radar · NCT01106677

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Last checked: Nov 20, 2026Latest source record: Jul 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,284

Actual

Start

May 2010

Primary completion

Oct 2011

Study completion May 2012

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e., treatment with a single drug) and have inadequate glycemic (blood sugar) control.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • PlaceboDrug

    One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.

  • CanagliflozinDrug

    One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.

  • SitagliptinDrug

    One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.

  • Metformin immediate releaseDrug

    The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From Baseline to Week 26Time frame: Day 1 (Baseline) and Week 26

Locations

125 sites in 22 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fountain Valley, California

  • Site not named

    National City, California

  • Site not named

    Northridge, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Bradenton, Florida

  • Site not named

    Brooksville, Florida

  • Site not named

    DeFuniak Springs, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Niceville, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Champaign, Illinois

  • Site not named

    Avon, Indiana

  • Site not named

    Fishers, Indiana

  • Site not named

    Franklin, Indiana

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Wichita, Kansas

  • Site not named

    Munfordville, Kentucky

  • Site not named

    Portland, Maine

  • Site not named

    Benzonia, Michigan

  • Site not named

    Interlochen, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Picayune, Mississippi

  • Site not named

    Florissant, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Mansfield, New Jersey

  • Site not named

    New Hyde Park, New York

  • Site not named

    Asheboro, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Kettering, Ohio

  • Site not named

    Oregon City, Oregon

  • Site not named

    Altoona, Pennsylvania

  • Site not named

    Tipton, Pennsylvania

  • Site not named

    East Providence, Rhode Island

  • Site not named

    Greer, South Carolina

  • Site not named

    Mt. Pleasant, South Carolina

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.